ImmunoPrecise Antibodies Ltd. (IPA) News
Filter IPA News Items
IPA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IPA News Highlights
- IPA's 30 day story count now stands at 7.
- Over the past 14 days, the trend for IPA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about IPA are AMP, DRUG and LAB.
Latest IPA News From Around the Web
Below are the latest news stories about IMMUNOPRECISE ANTIBODIES LTD that investors may wish to consider to help them evaluate IPA as an investment opportunity.
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call TranscriptImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call Transcript December 14, 2023 ImmunoPrecise Antibodies Ltd. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.09. Operator: Good morning, ladies and gentlemen. Thank you for joining us today for IPA’s Earnings Call covering the Second Quarter of Fiscal Year 2024. I am Sarah and I have […] |
ImmunoPrecise Antibodies Ltd. (IPA) Q2 2024 Earnings Call TranscriptImmunoPrecise Antibodies Ltd. (IPA) Q2 2024 Earnings Conference Call December 14, 2023 10:30 AM ET Company Participants Jennifer Bath - President and Chief Executive Officer Kristin Taylor - Chief Financial Officer Conference Call Participants Arthur He - H.C. Wainwright Will McHale - Ingalls & Snyder Presentation Operator Good morning, ladies and gentlemen. Thank you for joining us today for IPA’s Earnings Call covering the Second Quarter of Fiscal Year 2024. I am Sarah and I have the privilege of hosting this call. Before we commence, I would like to draw your attention to the fact that our discussion today may include forward-looking state... |
IPA Stock Earnings: ImmunoPrecise Antibodies Beats EPS, Beats Revenue for Q2 2024IPA stock results show that ImmunoPrecise Antibodies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. |
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*VICTORIA, British Columbia, December 14, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its second quarter of the 2024 fiscal year ("FY24"), which ended October 31, 2023. |
IPA Announces Closing of $1.265 Million Public Offering of Common SharesVICTORIA, British Columbia, December 08, 2023--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company"), today announced the closing of its $1.265 million underwritten public offering of 1,265,000 common shares, including 165,000 common shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price for each common share, before the underwriter’s discount and commissions, was $1.00. All of the securities in the |
ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14VICTORIA, BC / ACCESSWIRE / December 7, 2023 / ImmunoPrecise Antibodies (NASDAQ:IPA) ("IPA"), a leading company in AI-driven biotherapeutic research and technology, has recently announced important changes to its Board of Directors and upcoming financial ... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to dive into the biggest pre-market stock movers for Wednesday with a breakdown of all the latest news this morning! |
Why Is Carbon Revolution (CREV) Stock Down Today?Carbon Revolution stock is falling on Wednesday after shares of CREV gained yesterday with plans for a business update conference call. |
Why Is ImmunoPrecise Antibodies (IPA) Stock Down 39% Today?ImmunoPrecise Antibodies stock is falling on Wednesday after the company announced a $1.1 million public offering for shares of IPA. |
IPA Announces Pricing of $1.1 Million Public Offering of Common SharesVICTORIA, British Columbia, December 06, 2023--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company") today announced that it has priced its underwritten public offering of 1,100,000 common shares at a public offering price of $1.00 per share. All common shares in the underwritten public offering are to be sold by the Company. The Company expects the aggregate gross proceeds from this offering, to be approximately $1.1 million, before deducting the underwriting d |